Novartis Pharma B.V.
Location
Noord-Holland
Founded
1948-02-10
Website
Risk Signals
21161 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Novartis Pharma B.V.
Live alerts from global media, monitored by Business Radar
2025-05-08 (emarketer.com)
Gilead boosts US manufacturing amid Trump administration tariff, HIV healthcare challenges
Gilead joins pharma companies that are boosting US manufacturing amid Trump-induced challenges: Gilead Sciences faces unique challenges as a leading HIV drugmaker—Trump's tariff threats coincide with cuts to global HIV programs and LGBTQ+ healthcare initiatives.
Read more
2025-04-09 (bzbasel.ch)
High operation on the euro airport due to Trump's customs duties: 747 are still flying to the USA quickly
US President Donald Trump has announced further punitive tariffs for goods from abroad, sometimes they are already in force. The consequences are already noticeable.
Read more
2024-08-29 (pharmaceutical-technology.com)
Novartis teams up with Lindy Biosciences to improve biologic delivery
Lindy Biosciences will receive a $20m upfront payment from Novartis and up to $934m in additional payments.
Read more
2024-08-29 (europeanpharmaceuticalreview.com)
Novartis collaboration to innovate subcutaneous drug delivery
The multi-target agreement could enhance treatment convenience by improving subcutaneous administration options for patients.
Read more![[Top Trends] Liposomes Drug Delivery Market](https://images.businessradar.com/articles/c21dbb06-23b0-4e96-83c9-b45f31b36865)
2024-06-24 (amore.ng)
[Top Trends] Liposomes Drug Delivery Market
[Top Trends] Liposomes Drug Delivery Market | S.p.A., Gilead Sciences, Novartis - Amoré
Read more
2024-06-24 (amore.ng)
[Top Trends] Liposomes Drug Delivery Market
[Top Trends] Liposomes Drug Delivery Market | S.p.A., Gilead Sciences, Novartis - Amoré
Read more
2024-06-24 (amore.ng)
[Top Trends] Liposomes Drug Delivery Market
[Top Trends] Liposomes Drug Delivery Market | S.p.A., Gilead Sciences, Novartis - Amoré
Read more
2024-05-27 (amore.ng)
Liposomes Drug Delivery Market Size (Revenue)
Liposomes Drug Delivery Market Size (Revenue) | S.p.A., Gilead Sciences, Novartis - Amoré
Read more
2024-05-27 (amore.ng)
Liposomes Drug Delivery Market Size (Revenue)
Liposomes Drug Delivery Market Size (Revenue) | S.p.A., Gilead Sciences, Novartis - Amoré
Read more
2024-05-27 (amore.ng)
Liposomes Drug Delivery Market Size (Revenue)
Liposomes Drug Delivery Market Size (Revenue) | S.p.A., Gilead Sciences, Novartis - Amoré
Read more
2023-03-16 (itnonline.com)
Pluvicto Supply Shortage Update: What SNMMI is Doing
March 16, 2023 — A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients, which is having a profound negative impact on patient care.
Read more
2023-03-12 (cash.ch)
Press review from weekend 11 (March 11th/12th)
Below is a selection of articles on business-related topics from the press over the weekend:
Read more